KRON - Kronos Bio, Inc.
After hours:
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.6300 |
| Open | 1.6600 |
| Bid | 1.6000 x 1000 |
| Ask | 1.8300 x 800 |
| Day's Range | 1.5200 - 1.6900 |
| 52 Week Range | 1.2000 - 5.7400 |
| Volume | |
| Avg. Volume | 315,606 |
| Market Cap | 97.396M |
| Beta (5Y Monthly) | 1.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.2100 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.20 |
Fair Value
Related Research
GlobeNewswireKronos Bio Announces Participation in Upcoming Investor Conferences
SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: Jefferies Healthcare Conference on Thursday, June 8, 2023, at 8:30 a.m. ET; andGoldman Sachs 44th Annual Global Healthcare Conference on Thursday, June 15, 2023, at 10:40 a.m. PT. The fireside
Simply Wall St.The past year for Kronos Bio (NASDAQ:KRON) investors has not been profitable
Over the last month the Kronos Bio, Inc. ( NASDAQ:KRON ) has been much stronger than before, rebounding by 36%. But...
ZacksKronos Bio, Inc. (KRON) Reports Q1 Loss, Misses Revenue Estimates
Kronos Bio, Inc. (KRON) delivered earnings and revenue surprises of -6.98% and 89.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results
Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023 Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML on track to report recommended Phase 2 dose and initial data in Q4 2023 or Q1 2024 Katherine Vega Stultz and Roger Dansey, M.D., appointed to the Board of Directors $241.3 million in cash, cash equivalents and investments as of March 31, 2023, providing expected cash runway into 2H 2025 SAN MATEO, C
- GlobeNewswire
Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors
SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Roger Dansey, M.D., to the company’s Board of Directors. Dr. Dansey brings extensive experience in oncology drug development and a proven track record in the biotechnology industry. He currently serves as president, research and development of Seagen Inc. “Roger is an experienced l
- Simply Wall St.
Kronos Bio, Inc. (NASDAQ:KRON) insider upped their holding by 11% earlier this year
From what we can see, insiders were net buyers in Kronos Bio, Inc.'s ( NASDAQ:KRON ) during the past 12 months. That...
- GlobeNewswire
Kronos Bio Announces Changes to Board of Directors
Katherine Vega Stultz appointed to Board Current Board member Otello Stampacchia, Ph.D., stepped down SAN MATEO, Calif. and CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Katherine Vega Stultz to its Board of Directors, replacing Otello Stampacchia, Ph.D., who stepped down as of March 31, 2023. “We are very pleased to welcome Katherine to our Board
- GlobeNewswire
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results
First patient dosed in expansion portion of KB-0742 Phase 1/2 study, with initial efficacy results expected in 2H 2023 Recommended Phase 2 dose and initial data from Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML on track to report in Q4 2023 or Q1 2024 Discovery collaboration with Genentech underway $247.9 million in cash, cash equivalents and investments as of December 31, 2022, providing expected cash runway into the second half of 2025 SAN MATEO, Calif.
- GlobeNewswire
Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference
SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 43rd Annual Cowen Health Care Conference, taking place March 6-8, 2023, in Boston, Massachusetts. Kronos Bio President and Chief Executive Officer Norbert Bischofberger, Ph.D., will participate in the “Novel Oncology Targets” panel discussion on Tuesday, March 7, at 9:10 a.m. ET.
American City Business JournalsDeals, data kick off biotech's big JPM Week
Biotech companies are trying to get in front of investors and potential partners — and regulators — with news ahead of the big J.P. Morgan Healthcare Conference in San Francisco.
- GlobeNewswire
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology
Kronos Bio will receive a $20 million upfront payment and could receive up to an additional $554 million in milestone payments Agreement will leverage Kronos Bio’s expertise in transcriptional regulatory networks and its proprietary drug discovery platform SAN MATEO, Calif. and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced today that it has entered into a discovery collabor
- Simply Wall St.
We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
ZacksHere's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 31% in 4 Weeks
Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- GlobeNewswire
Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting
Lanraplenib is being evaluated in ongoing Phase 1b/2 trial in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated AML Additional presentations highlight Kronos Bio’s collaboration with academic cooperative groups to better understand the predictive value of measurable residual disease SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, is p
- GlobeNewswire
Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial
Kronos Bio to move into Phase 2 stage of study, evaluating compound in patients with MYC-amplified and other transcriptionally addicted tumors Data demonstrate achievement of target engagement goal, differentiated pharmacokinetic profile and long half-life Detailed results from Phase 1 stage of study and initial data from Phase 2 expansion stage to be presented at medical conference in second half of 2023 SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc.
ZacksHere's Why Kronos Bio, Inc. (KRON) is Poised for a Turnaround After Losing 23.8% in 4 Weeks
Kronos Bio, Inc. (KRON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Simply Wall St.
Insiders might want to re-evaluate their US$2.4m stock purchase as Kronos Bio, Inc. (NASDAQ:KRON) drops to US$145m
The recent price decline of 11% in Kronos Bio, Inc.'s ( NASDAQ:KRON ) stock may have disappointed insiders who bought...
- GlobeNewswire
Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results
Earlier today, the company announced prioritization of clinical portfolio to focus on next-generation SYK inhibitor, lanraplenib and CDK9 inhibitor, KB-0742 $270.3 million in cash, cash equivalents and investments as of Sept. 30, 2022, with expected cash runway into Q2 2025 SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and
- GlobeNewswire
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742
Company to discontinue Phase 3 entospletinib trial for strategic reasons Enrollment continues for Phase 1/2b trial in relapsed/refractory AML with Kronos Bio’s next generation SYK inhibitor, lanraplenib Company on track to provide KB-0742 update from ongoing Phase 1/2 clinical trial in Q4 With $270.3 million in cash, cash equivalents and investments as of Sept. 30, 2022, Kronos Bio extends expected cash runway from Q4 2024 into Q2 2025 Conference call and webcast scheduled for today at 4:30 p.m.
- GlobeNewswire
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022
Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742 Phase 1/2 Clinical Trial in Q4 2022SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present preclinical data in a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The meeting will be held from Oct. 26
- GlobeNewswire
Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference
SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the H.C. Wainwright 24th Annual Global Investment Conference. An on-demand webcast of the presentation will be available on Monday, September 12, 2022, at 7 a.m. ET. The webcast will be available on the Investors and Media section of the Kronos Bio website
BenzingaKronos Bio Starts Dosing In Early-Stage Leukemia Study With Next-Gen SYK Inhibitor
The first patient was dosed in Kronos Bio Inc's (NASDAQ: KRON) Phase 1b/2 trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). Lanraplenib is the company's next-generation spleen tyrosine kinase (SYK) inhibitor. The Phase 1b/2 lanraplenib trial is being conducted in two stages: a dose-escalation stage and an expansion stage. The first stage is evaluating the initial safety, pharmacokinetic and anti-leukemic activity
- GlobeNewswire
Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia
SAN MATEO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in a Phase 1b/2 clinical trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). Lanraplenib is the company’s next-generation spleen tyrosine kinase (SYK) inhibitor. In addition to lanraplenib, Kronos Bio is
CNW GroupKronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of diagnostic kits and services for oncology, today announced their agreement to develop a companion diagnostic (CDx) for use with Kronos Bio's investigational therapy, entospletinib. Entospletinib is Kronos Bio's lead clinical compound, currently in the ongoing Phase 3 registrational AGILITY study for the treatment of newly diagnosed NPM1-mutated acute